SequelSEC

BIOADAPTIVES, INC. BDPT

Pharmaceutical Preparations · CIK 0001575142 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$4.99K
Fiscal year ended 2026-06-30
Operating income
-$197.18K
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$252.18KMarket value of stock held by non-affiliates, as stated on the cover page for 2025-12-31
Float per share$0.02Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue13.8×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-12-31, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio0.09x5th
CapEx / revenue98.5%93th
Net margin-8523.4%11th
FCF margin-2921.7%13th
Operating margin-5701.8%15th
SBC / revenue156.9%74th
Revenue YoY growth44.3%74th
Gross margin68.4%45th

BIOADAPTIVES, INC. (BDPT) reported revenue of $4.99K and net income of $150.09K for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BIOADAPTIVES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

BIOADAPTIVES, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$4.99K$5.51K$10.43K$4.63K$3.22K$0$0$0$675$11.99K
Cost of revenue$748$1.40K$2.84K$781$2.16K$0$0$0$246$8.39K
Gross profit$4.24K$4.11K$7.58K$3.85K$1.06K$0$0$0$429$3.60K
Operating income-$197.18K-$198.22K-$248.12K-$265.69K-$279.22K-$249.15K-$337.34K-$121.94K-$92.98K-$49.83K
Net income$150.09K-$111.09K-$823.35K-$379.50K-$157.91K-$197.14K-$371.79K-$37.65K-$183.02K-$306.71K
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 281.20Mshares 12.01MUnavailableshares 10.24Mshares 9.53Mshares 9.05MUnavailableshares 8.21Mshares 2.99Mshares 7.70M
Pretax income$150.09K-$111.09K-$823.35K-$379.50K-$157.91K-$197.14K-$371.79K-$37.65K-$183.02KUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$0.00$-0.01Unavailable$-0.04$-0.02$-0.02Unavailable$0.00$0.06$-0.04
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$177.74K$181.05K$228.26K$250.97K$197.89K$143.38K$258.62K$40.40K$4.62K$31.67K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

BIOADAPTIVES, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalentsUnavailableUnavailable$215.20KUnavailableUnavailableUnavailable$261.88KUnavailableUnavailableUnavailable
Total assets$78.77K$135.95K$225.90K$124.36K$272.52K$110.45K$261.88K$46.39K$8.74K$58.67K
Current assets$67.77K$123.45K$211.90K$108.86K$255.52K$110.45K$261.88K$46.39K$8.74K$40.67K
Total liabilities$1.84M$2.27M$2.36M$1.59M$1.41M$1.68M$1.73M$1.85M$1.93M$1.86M
Current liabilities$1.84M$2.27M$2.36M$1.59M$1.41M$1.68M$1.73M$1.85M$1.93M$1.86M
Total equity incl. NCI-$1.77M-$2.14M-$2.13M-$1.47M-$1.14M-$1.57M-$1.46M-$1.81M-$1.87M-$1.80M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$36.05K$42.97K$44.71K$44.23K$39.57K$40.58K$19.12K$0$6.00K$18.57K
Accounts receivableUnavailableUnavailableUnavailable$59$59Unavailable$0UnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

BIOADAPTIVES, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$44.38K-$84.84K-$155.83K-$151.31K-$110.98K-$97.91K-$100.54K-$56.34K-$51.46K-$41.18K
Capital expendituresUnavailableUnavailable$0$0UnavailableUnavailable$0$0UnavailableUnavailable
Investing cash flowUnavailableUnavailable$0$0UnavailableUnavailable$0$0UnavailableUnavailable
Financing cash flowUnavailableUnavailable$255.00K$0UnavailableUnavailable$194.12K$100.00KUnavailableUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailableUnavailableUnavailable$28.67KUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

BIOADAPTIVES, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailable-$155.83K-$151.31KUnavailableUnavailable-$100.54K-$56.34KUnavailableUnavailable
Gross margin85.0%74.6%72.7%83.1%33.0%UnavailableUnavailableUnavailable63.6%30.0%
Operating margin-3953.0%-3594.8%-2379.6%-5735.9%-8674.1%UnavailableUnavailableUnavailable-13774.5%-415.5%
FCF marginUnavailableUnavailable-1494.5%-3266.6%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable890.6%UnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.04x0.05x0.09x0.07x0.18x0.07x0.15x0.03x0.00x0.02x
Revenue YoY growth55.0%UnavailableUnavailableUnavailable376.9%-100.0%-100.0%-100.0%-71.1%255.3%
Net margin3009.0%Unavailable-7896.3%-8193.0%-4905.7%UnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailable0.0%0.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BDPT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-19View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-04-14View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.